
Vivos Therapeutics (VVOS) Stock
Developer of oral appliances for sleep apnea. Here's the price, business snapshot, and what's worth knowing about Vivos Therapeutics in October 2026.
Vivos Therapeutics Inc (VVOS) is a micro‑cap healthcare company developing and commercialising oral appliance therapies and airway‑centred dental solutions aimed at treating sleep‑disordered breathing, including mild‑to‑moderate sleep apnoea. The company’s model centres on bespoke dental devices designed to expand the upper airway, distributed through a network of trained providers and partner clinics. With a market capitalisation of roughly $20.7 million, VVOS is a small, illiquid stock prone to price volatility; revenues and profitability have been variable as the business invests in clinical validation and market expansion. Key factors for investors include regulatory oversight, reimbursement environments, clinical adoption rates and intellectual property strength. Potential upside exists if clinical acceptance and sales scale, but risks are material and execution dependent. This is general educational information, not personalised investment advice. Values can fall as well as rise; prospective investors should assess suitability for their circumstances and consider professional guidance.
Vivos Therapeutics (VVOS) Stock Forecast
Analyst price target, next 12 months
$3.75
+2370.4% vs today's $0.15
Price range over the last 12 months
Close to its 12-month low
Analysts covering Vivos Therapeutics have a consensus 12-month target of $3.75, above the current price of $0.15.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 29 Jul 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VIVOS Therapeutics stock with a target price of $3.75, indicating strong potential growth.
Financial Health
Vivos Therapeutics is generating solid revenue and cash flow, indicating a healthy financial position.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Sleep therapy growth
Rising awareness of sleep apnoea and interest in non‑CPAP options could create market opportunity, though clinical adoption and reimbursement will determine impact.
Small‑cap volatility
With a market cap around $20M, shares can be illiquid and volatile; this profile suits investors ready to accept higher risk and potential price swings.
Regulation and adoption
Regulatory approvals, clinical evidence and provider uptake are key growth levers—outcomes here can materially influence future performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.